European Leukemia Trial Registry
Trial: AML APL AIDA 2000 SAL

More Details
Title risk adapted treatment of acute acute promyelocytic leukemia (APL)
Scientific Title Recommendation for risk-adapted treatment of acute promyelocytic leukemia (APL) in the framework of the AML-SHG-Study Group (AIDA2000)
Short Title AML APL AIDA 2000 SAL
Trialgroup DSIL
Type of Trial multicentric
Disease Acute myeloid leukemia(AML) FAB M3 (APL)
Age All ages
Status Closed
Start of Recruitment 09.12.2000
Leader Ehninger, Prof. Dr. med., Gerhard
Contactperson

Study Physician
Schaich, Prof. Dr. med., Markus
Tel: +49 (0)7195 591-39240
Fax: +49 (0)7195 591-939240
Email: markus.schaich@rems-murr-kliniken.de

Study Centre
Soucek, Silke
Tel: +49 (0)351 458 4251
Fax: +49 (0)351 458 4367
Email: silke.soucek@uniklinikum-dresden.de

Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Remark for patients with contraindications against study medication, monotherapy with ATRA can be considered
created 04.07.2006 Anja Hellenbrecht
changed 10.07.2013 Sina Hehn
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org